ClinicalTrials.gg
RecruitingNCT06245109PREDICTUpdated Apr 30, 2026

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

A Phase 4 interventional study of Duloxetine and Celecoxib in Knee Osteoarthritis, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 41 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Northwestern University · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
41 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing duloxetine in Osteoarthritis, Knee — 4 open to participants now, 4 under way, none of them phase 3. duloxetine · Osteoarthritis, Knee.

Planned enrollment
7th of 19
180 · median 102
Started
2024
with 1 other
Phase 4
6 of 19
3 open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
Northwestern University

Among the 19 studies testing duloxetine in Osteoarthritis, Knee, this one is the 7th largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 4, and was the 16th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 19 studies testing duloxetine in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About duloxetine

duloxetine: first FDA approval 2004 (CYMBALTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 41 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing duloxetine in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have a knee Xray, (optional) MRIs of the brain and knee, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to try to predict which participants will respond to the treatment.

Read the detailed description

This longitudinal study will screen and enroll 180 participants diagnosed with knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks' duration with a repeat-treatment design. An equal number of participants (60 per group) will be randomly assigned in a 1:1:1 ratio, stratified by sex and current opioid use, to one of three treatment groups after they qualify to enter the study. The treatment groups will celecoxib (200 mg qd), duloxetine (60 mg qd, with an initial and final 7-day titration at 30 mg qd), or matching placebo (one capsule qd). This aim of this study is to identify specific biomarkers in individual people with knee osteoarthritis pain that will allow definition of responder phenotypes distinct for different therapeutic interventions.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • knee oa
  • knee osteoarthritis
  • osteoarthritis
  • knee pain
04

Who can participate

Ages eligible
41 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age greater than 40 years, with no racial/ethnic restrictions;
  2. Meet American College of Radiology criteria for knee osteoarthritis (OA) based on radiographic evidence;
  3. Knee pain most days of the week for the past month at screening;
  4. Must have average pain score for the week prior to baseline of ≥ 4.0 (on a 0 to 10 Numeric Rating Scale)
  5. Must complete pain ratings on at least 4 out of 7 days prior to baseline;
  6. Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires;
  7. Must be in generally stable health;
  8. Must be able to return for all clinic visits;
  9. Willing to remain stable on any concomitant therapies (Transcutaneous Electrical Nerve Stimulation (TENS) unit, ice, glucosamine chondroitin, cannabinoids, etc.);
  10. Must sign an document after complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate;
  11. Ambulatory with or without a cane, brace(s), or walking stick (use of walker or wheelchair will be exclusionary);
  12. Glucagon-like peptide 1 (GLP-1) agonists or other weight-loss treatment permitted if started more than 3 months prior to screening with no significant change in weight (+/- 11 lbs) over the past 30 days;

Exclusion criteria

Exclusion Criteria:

  1. Evidence of rheumatoid arthritis, ankylosing spondylitis, other inflammatory arthropathy;
  2. Functional class IV congestive heart failure;
  3. Significant other medical disease such as uncontrolled hypertension, untreated diabetes mellitus, coronary or peripheral vascular disease, chronic obstructive lung disease, or liver disease (liver function tests > );
  4. Current use of illicit drugs or history (in last 12 months) of alcohol or drug abuse;
  5. Current cannabinoid use for knee pain;
  6. High dose opioid use, as defined as > 50mg morphine equivalent/day;
  7. Any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk;
  8. In the judgment of the investigator, unable or unwilling to follow protocol and instructions;
  9. Intra-axial implants (e.g., spinal cord stimulators or pumps);
  10. Currently breastfeeding, pregnant, or planning to become pregnant during the study;
  11. Chronic neurologic conditions, e.g., Parkinson's;
  12. Renal insufficiency (creatinine >1.5 mg/dl);
  13. Previous history of peptic ulcer or gastrointestinal bleeding;
  14. Current use of anticoagulants or inhibitors other than aspirin at ≤325 mg/day;
  15. Allergy to sulfonamide drugs, duloxetine, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetaminophen;
  16. Acute myocardial infarction or coronary artery bypass graft surgery, in the past 12 months;
  17. Recent injection into the index knee of hyaluronic acid or other substance in the last 6 months, or in the last 90 days;
  18. Lactose allergy;
  19. Current use of selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and/or tricyclic antidepressants (TCAs) at a therapeutic dose. Occasional use of these medications as a sleep aid will be allowed; however, participants will need to agree to remain on a stable dose of the medication while in the study;
  20. Uncontrolled narrow-angle glaucoma;
  21. within 2 years of screening, with the exception of squamous cell carcinoma, basal cell carcinoma and prostate cancer (grade group 1);
  22. Active treatment for cancer other than superficial skin cancer; or
  23. Nerve ablation performed on the index knee within 12 months of screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Duloxetine

    Duloxetine 60mg tablet, daily (with an initial and final 7-day titration at 30 mg, daily)

    Drug: Duloxetine

  • Active comparator
    Celecoxib

    Celecoxib 200 mg tablet, daily

    Drug: Celecoxib

  • Placebo comparator
    Placebo

    Matching placebo tablet, daily

    Drug: Placebo

Interventions

  • 60 mg, oral

    Also known as: Cymbalta

  • 200 mg, oral

    Also known as: Celebrex

  • DrugPlacebo

    Matching placebo, oral

06

What researchers measure

Primary outcomes

  1. Percentage of Individuals with at least 30% Pain Response to treatment

    At least 30% improvement from baseline in "weekly average daily pain" measured using a numeric rating scale (0-10) with 0 = no pain and 10 = worst pain

    Time frame: Baseline to end of first treatment period (week 6) and second treatment period (week 16)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2028, 48 months after the start.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 48 months is above that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 7, 2024
StartActual
Feb 26, 2024
Primary completionEst.
Mar 15, 2028
CompletionEst.
Mar 15, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06245109
Responsible party
Thomas J. Schnitzer (Professor, Northwestern University) — Principal investigator
First posted
Feb 7, 2024
Start date
Feb 26, 2024
Primary completion
Mar 15, 2028 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Graeme Witte
Contact
graeme.witte@northwestern.edu
3125034163
Narina Simonian, BS, CCRC
Contact
n-simonian@northwestern.edu
3125035780
Thomas J Schnitzer, MD, PhD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Duloxetine · Celecoxib

Start the discussion